Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Flag link:
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer
Pharmaceutical Business Review
Merck
Keytruda
FDA
esophageal cancer
gastroesophageal cancer
Flag link:
Merck gets positive CHMP opinion for Keytruda as first-line treatment for dMMR colorectal cancer
Merck gets positive CHMP opinion for Keytruda as first-line treatment for dMMR colorectal cancer
Pharmaceutical Business Review
Merck
CHMP
Keytruda
colorectal cancer
Flag link:
Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq?
Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq?
Endpoints
Merck
Keytruda
triple negative breast cancer
Flag link:
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
advanced renal cell carcinoma
Flag link:
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Flag link:
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer
Fierce Pharma
Regeneron
Sanofi
Libtayo
FDA
priority review
non-small cell lung cancer
Merck
Keytruda
Flag link:
Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda
Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda
BioSpace
Sanofi
Merck
THOR-707
Keytruda
solid tumors
Flag link:
Merck raises annual profit outlook as Keytruda drives profit beat
Merck raises annual profit outlook as Keytruda drives profit beat
CNBC
Merck
earnings
Keytruda
Flag link:
Merck touts new data for Keytruda combos in NSCLC at North American conference
Merck touts new data for Keytruda combos in NSCLC at North American conference
Endpoints
Merck
clinical trials
Keytruda
non-small cell lung cancer
IASLC
Flag link:
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
FDA approves expanded indication for Merck’s KEYTRUDA in adult patients with relapsed or refractory cHL
Pharmaceutical Business Review
Merck
FDA
Keytruda
Hodgkin's lymphoma
Flag link:
Sensei raises $29M to advance anti-cancer bacteriophage pipeline
Sensei raises $29M to advance anti-cancer bacteriophage pipeline
Fierce Biotech
Sensei Biotherapeutics
SNS-301
Merck
Keytruda
bacteriophage
Flag link:
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study
BioSpace
ALX Oncology
Merck
head and neck cancer
ALX148
Keytruda
Flag link:
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
Fierce Pharma
ESMO
Roche
Tecentriq
triple negative breast cancer
Merck
Keytruda
Flag link:
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
ovarian cancer
colorectal cancer
Flag link:
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
Fierce Pharma
Merck
ESMO
bladder cancer
metastatic bladder cancer
Keytruda
Flag link:
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Flag link:
Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Pharmaforum
Highlight Therapeutics
melanoma
BO-112
Keytruda
Merck
Flag link:
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Flag link:
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
BioSpace
Merck
Novocure
clinical trials
tumor treating fields
Keytruda
non-small cell lung cancer
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »